The FDA posted a final guidance, "Coordinated Development of Antimicrobial Susceptibility Test Devices," aimed at minimizing the time between the approval of new antimicrobial drugs and clearance of antimicrobial susceptibility tests used to determine the potential effectiveness of those drugs and to provide recommendations to drug- and device makers on how to work together to facilitate timely clearance.